Reducing leukocyte interference in non-competitive immunoassays

• US 8,377,669 B2
• Filed: 11/17/2009
• Issued: 02/19/2013
• Est. Priority Date: 11/17/2009
• Status: Active Grant

• Current Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories)
• Inventors: Campbell, John Lewis Emerson, Moss, Adam Roger, Davis, Graham
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US12/620,179
• Publication Number:
  US 20110117580A1
• Time in Patent Office: 1,190 Days
• Field of Search: 435/7.1, 435/7.2, 435/7.24, 435/7.32, 435/7.9, 435/7.92, 435/7.93, 435/7.94, 435/287.2, 435/287.9, 436/506, 436/512, 436/513, 436/518, 436/523, 436/524, 436/528, 436/529, 436/540, 436/166, 436/175, 436/177, 422/73, 422/417, 422/425, 422/426, 422/430, 422/82.01, 422/82.03, 422/82.11, 422/527
• US Class Current: 435/175
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: G01N 33/54393 Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials

Abstract

The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads; and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.

Claims

1. A kit for performing a sandwich immunoassay for an analyte suspected of being present in a whole blood sample, comprising beads opsonized to leukocytes, a substrate immobilized first antibody to the analyte and a labeled second antibody to the analyte, wherein the opsonized beads are present in an amount in excess of the leukocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample.

2. The kit of claim 1, wherein the analyte is selected from the group consisting of B-type natriuretic peptide (BNP), pro b-type natriuretic peptide (proBNP), N-terminal pro b-type natriuretic peptide (NTproBNP), cardiac troponin I (cTnI), troponin T (TnT), human chorionic gonadotrpoin (HOG), thyroid-simulating hormone (TSH), prostate specific antigen (PSA), D-dimer, c-reactive protein (CRP), myoglobin, Neutrophil Gelatinase-associated Lipocalin (NGAL), creatine kinase (CKMB) and myeloperoxidase.

3. The kit of claim 1, wherein the opsonized beads comprise substrate beads coated with non-human IgG or fragments thereof.

4. The kit of claim 3, wherein the substrate beads are formed of a material selected from the group consisting of polystyrene, polyacrylic acid, and dextran.

5. The kit of claim 1, wherein the opsonized beads comprise substrate beads coated with a material or fragment thereof selected from the group consisting of a protein, a bacterium, a virus and a xenobiotic.

6. The kit of claim 1, wherein the opsonized beads are stabilized bacterium or bacterial spores.

7. The kit of claim 1, wherein the opsonized beads have an average particle size of from 0.01 μ

m to 20 μ

m.

8. The kit of claim 1, wherein the opsonized beads have an average particle size of from 0.1 μ

m to 5 μ

m.

9. The kit of claim 1, wherein the opsonized beads are present in an amount sufficient to provide a dissolved bead concentration of at least 10⁴ beads per microliter of sample.

10. The kit of claim 1, wherein the substrate immobilized first antibody is attached to a sensor selected from the group consisting of an amperometric electrode, a potentiometric electrode, a conductimetric electrode, an optical wave guide, a surface plasmon resonance sensor, an acoustic wave sensor and a piezoelectric sensor.

11. The kit of claim 1, wherein the substrate immobilized first antibody is attached to an assay bead, and the assay bead is attached to an amperometric electrode.

12. The kit of claim 1, wherein the opsonized beads and the second labeled antibody are in one or more dissolvable dry reagent coatings.

13. The kit of claim 1, wherein said labeled second antibody is labeled with a label selected from the group consisting of a radiolabel, an enzyme, a chromophore, a fluorophore and a chemiluminescent species.

14. The kit of claim 1, wherein said labeled second antibody is labeled with an enzyme selected from the group consisting of alkaline phosphatase, glucosidase, diaphorase, horseradish peroxidase and glucose oxidase.

15. The kit of claim 1, wherein said blood sample is whole blood amended with an anticoagulant.

16. The kit of claim 1, wherein white blood cells in the blood sample preferentially seek to phagocytose the beads.

17. A cartridge for performing a sandwich immunoassay for an analyte suspected of being present in a whole blood sample, the cartridge comprising:

(a) a sample inlet for receiving the blood sample;

(b) a metering chamber for metering the blood sample to form a metered sample;

(c) one or more dry reagent coating layers comprising beads opsonized to leukocytes and a labeled antibody to the analyte, wherein the opsonized beads are present in an amount in excess of the leukocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample;

(d) an electrode comprising an immobilized antibody to the analyte; and

(e) one or more pumping elements for moving a metered sample, fluidized beads, and the labeled antibody to the electrode.

18. The cartridge of claim 17, wherein the analyte is selected from the group consisting of BNP, proBNP, NTproBNP, cTnI, TnT, HCG, TSH, PSA, D-dimer, CRP, myoglobin, NGAL, CKMB and myeloperoxidase.

19. The cartridge of claim 17, wherein the opsonized beads comprise substrate beads coated with non-human IgG or fragments thereof.

20. The cartridge of claim 19, wherein the substrate beads are formed of a material selected from the group consisting of polystyrene, polyacrylic acid, and dextran.

21. The cartridge of claim 17, wherein the opsonized beads have an average particle size of from 0.01 μ

m to 20 μ

m.

22. The cartridge of claim 17, wherein the opsonized beads are present in an amount sufficient to provide a dissolved bead concentration of at least 10⁴ beads per microliter of sample.

23. The cartridge of claim 17, wherein the one or more dry reagent coating layers are disposed within the metering chamber.

24. The cartridge of claim 17, wherein said blood sample is whole blood amended with an anticoagulant.

25. The cartridge of claim 17, wherein white blood cells in the blood sample preferentially seek to phagocytose the beads.

26. A method of performing a sandwich immunoassay for an analyte suspected of being present in a whole blood sample comprising:

(a) exposing a whole blood sample suspected of containing the analyte to beads opsonized to leukocytes, and wherein the opsonized beads are present in an amount in excess of the leukocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample;

a substrate immobilized first antibody to the analyte; and

a labeled second antibody to form a complex comprising said first antibody, said analyte and said second antibody; and

(b) detecting and measuring the amount of labeled ternary complex formed in step a) so as to determine the presence and amount of analyte in the whole blood sample.

27. The method of claim 26, wherein the opsonized beads contact the blood sample under conditions effective for leukocytes in the sample to preferentially phagocytose the opsonized beads.

28. The method of claim 26, wherein the analyte is selected from the group consisting of B-type natriuretic peptide (BNP), pro b-type natriuretic peptide (proBNP), N-terminal pro b-type natriuretic peptide (NTproBNP), cardiac troponin I (cTnI), troponin T (TnT), human chorionic gonadotrpoin (HCG), thyroid-simulating hormone (TSH), prostate specific antigen (PSA), D-dimer, c-reactive protein (CRP), myoglobin, Neutrophil Gelatinase-associated Lipocalin (NGAL), creatine kinase (CKMB) and myeloperoxidase.

29. The method of claim 26, wherein the opsonized beads comprise substrate beads coated with non-human IgG or fragments thereof.

30. The method of claim 29, wherein the substrate beads are formed of a material selected from the group consisting of polystyrene, polyacrylic acid, and dextran.

31. The method of claim 26, wherein the opsonized beads have an average particle size of from 0.01 μ

m to 20 μ

m.

32. The method of claim 26, wherein the opsonized beads have an average particle size of from 0.1 μ

m to 20 μ

m.

33. The method of claim 26, wherein the opsonized beads are present in an amount sufficient to provide a dissolved opsonized bead concentration of at least 10⁴ beads per microliter of sample.

34. The method of claim 26, wherein said blood sample is whole blood amended with an anticoagulant.

35. The method of claim 26, wherein the blood sample is mixed with the opsonized beads, then mixed with the substrate immobilized first antibody, and then mixed with the labeled second antibody.

36. The method of claim 26, wherein the blood sample is mixed with the opsonized beads, the substrate immobilized first antibody, and the labeled second antibody at substantially the same time.

37. The method of claim 26, wherein the blood sample is mixed with the substrate immobilized first antibody and the labeled second antibody at substantially the same time.

38. The method of claim 26, wherein the blood sample is mixed with the opsonized beads and the labeled second antibody at substantially the same time, and before the blood sample is mixed with the substrate immobilized first antibody.

39. A method of substantially ameliorating white blood cell accumulation on an analyte immunosensor comprising antibody-coated assay beads to the analyte immobilized on an electrode, the method comprising the steps of:

(a) mixing a whole blood sample suspected of containing an analyte with beads opsonized to leukocytes to form an amended sample wherein white blood cells in the sample preferentially seek to phagocytose the beads opsonized to leukocytes, wherein the opsonized beads are present in an amount in excess of the leucocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample, and

(b) contacting the amended sample with an immunosensor.

40. The method of claim 39, wherein the beads opsonized to leukocytes are present in an amount sufficient to provide a dissolved opsonized bead concentration of at least 10⁴ beads per microliter of sample.

41. A method of performing an immunoassay for an analyte suspected of being present in a whole blood sample comprising:

(a) mixing a whole blood sample suspected of containing an analyte with an excess amount of beads opsonized to leukocytes sufficient to substantially sequester any leucocytes present in the sample to form an amended sample wherein white blood cells in the sample preferentially seek to phagocytose the opsonized beads;

(b) contacting the amended sample with an immunosensor comprising antibody-coated assay beads to the analyte immobilized on an electrode forming a complex between said antibody-coated assay bead, said analyte and a second labeled antibody;

(c) washing said blood sample from said immunosensor; and

(d) detecting and measuring the amount of said labeled ternary complex formed in step b) onto said immunosensor and relating the amount of said labeled complex to the concentration of the analyte present in the whole blood sample.

42. A method of performing a sandwich immunoassay for an analyte suspected of being present in a whole blood sample, comprising:

(a) mixing a whole blood sample suspected of containing an analyte with an excess amount of opsonized beads to leucocytes sufficient to substantially sequester any leucocytes present in the sample to form an amended sample wherein white blood cells in the sample preferentially seek to phagocytose the opsonized beads;

(b) contacting the amended sample with antibody-coated assay beads to the analyte under conditions effective to form a complex between said antibody-coated assay bead, said analyte and a second labeled antibody;

(c) washing said blood sample from said antibody-coated assay beads; and

(d) detecting and measuring the amount of said labeled ternary complex formed in step b) and relating the amount of said labeled complex to the concentration of the analyte present in the whole blood sample.

43. A test cartridge for performing an immunoassay for an analyte suspected of being present in a whole blood sample, the test cartridge comprising an immunosensor in a conduit, said immunosensor having an immobilized first antibody to the analyte, and said conduit having a dry reagent coating disposed therein, the dry reagent coating comprising beads opsonized to leukocytes, wherein the opsonized beads are present in an amount in excess of the leucocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample and a second labeled antibody to said analyte and being configured to dissolve into said blood sample.

44. A kit for performing a sandwich immunoassay for an analyte suspected of being present in a whole blood sample, comprising beads opsonized to leukocytes, a substrate immobilized first antibody to the analyte and a labeled second antibody to the analyte, wherein the opsonized beads are present in an amount sufficient to provide a dissolved bead concentration of at least 5 micrograms per microliter of sample which is an amount in excess of the leucocytes in the blood sample sufficient to substantially sequester any leucocytes present in the sample.

45. The kit of claim 44, wherein the opsonized beads are present in an amount sufficient to provide a dissolved bead concentration of at least 10 micrograms per microliter of sample.

46. The kit of claim 44, wherein the opsonized beads are present in an amount sufficient to provide a dissolved bead concentration of at least 15 micrograms per microliter of sample.